OBX 8-K 2026-11-12

Obsidian Therapeutics, Inc. (OBX) 8-K dated 2026-11-12 — accession 0001193125-26-458347.

Obsidian Therapeutics, Inc. (OBX) common stock.

Obsidian Therapeutics, Inc. filed a 8-K on 2026-11-12. Accession 0001193125-26-458347.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported OBX revenue for 2026-06-30 was $0. Net income was -$25.9M.

Not investment advice. The OBX SEC hub lists recent forms. The stock page is the research view.